MSAM
JNCE

Moloney Securities Asset Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Moloney Securities Asset Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-243,950
Closed -$451K – 461
2023
Q1 		$451K Sell
243,950
-238,500
-49% -$295K 0.08% 255
2022
Q4 		$536K Buy
482,450
+355,119
+279% +$506K 0.12% 208
2022
Q3 		$298K Sell
127,331
-52,200
-29% -$185K 0.07% 271
2022
Q2 		$544K Sell
179,531
-73,300
-29% -$357K 0.13% 201
2022
Q1 		$1.72M Sell
252,831
-63,344
-20% -$451K 0.33% 82
2021
Q4 		$2.64M Buy
316,175
+33,925
+12% +$280K 0.45% 51
2021
Q3 		$2.1M Buy
282,250
+265,650
+1,600% +$1.65M 0.38% 77
2021
Q2 		$113K Sell
16,600
-3,000
-15% -$24.9K 0.02% 410
2021
Q1 		$201K Buy
+19,600
New +$215K 0.04% 382

Other funds holding JNCE

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Moloney Securities Asset Management's JNCE Position: Q2 2023 in Review

Moloney Securities Asset Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 243,950 shares — an estimated $451K sold.

Moloney Securities Asset Management first reported a position in JNCE in Q1 2021 and held it in 9 quarters. The position peaked at $2.64M in Q4 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

  • Moloney Securities Asset Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Moloney Securities Asset Management sold 243,950 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $451K.
  • Moloney Securities Asset Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
  • Moloney Securities Asset Management's Jounce Therapeutics, Inc. Common Stock position peaked at $2.64M in Q4 2021.
  • 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Moloney Securities Asset Management's 13F filing for Q2 2023, filed 31 Jul 2023.